Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 1,300 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,115 shares of the biopharmaceutical company’s stock after acquiring an additional 1,300 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Alnylam Pharmaceuticals were worth $6,851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Compass Capital Corp MA ADV purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $188,000. Allianz Asset Management GmbH lifted its stake in shares of Alnylam Pharmaceuticals by 306.1% during the 4th quarter. Allianz Asset Management GmbH now owns 108,871 shares of the biopharmaceutical company’s stock valued at $25,618,000 after buying an additional 82,065 shares in the last quarter. Ieq Capital LLC lifted its stake in shares of Alnylam Pharmaceuticals by 825.5% during the 4th quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company’s stock valued at $9,131,000 after buying an additional 34,613 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 6,200.0% during the 4th quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 248 shares in the last quarter. Finally, Truist Financial Corp lifted its stake in shares of Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after buying an additional 2,539 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $248.94 on Tuesday. The company has a market capitalization of $32.23 billion, a price-to-earnings ratio of -114.72 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm’s 50-day moving average is $254.24 and its 200 day moving average is $262.90. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on ALNY. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright lifted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Finally, Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $303.83.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares in the company, valued at $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,986 shares of company stock worth $20,397,849. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.